[46] reported that cancers most strongly associated with KRAS mutations include pancreatic cancer (80%), cholangiocarcinoma (45%), and lung cancer (32%), all of which exhibit higher mutation frequencies than HCC, where the KRAS mutation rate is approximately 5.6%. This evidence concerns the gene KRAS and hepatocellular carcinoma.